Omvoh Market Report 2026

Omvoh Market Overview

• The Omvoh market growth in the historic period has been driven by advancements in inflammatory bowel disease research, increasing diagnosis of ulcerative colitis • Market expansion is supported by growing adoption of targeted immunology therapies, expansion of biologic maintenance treatments • Growth Driver: Impact Of Rising Autoimmune Disease On The Market • Market Trend: Positive Recommendation For IL-23p19 Antagonist In Treating Active Crohn's Disease • North America was the largest region in 2025.

What Is Covered Under Omvoh Market?

Omvoh is a prescription medication containing the active ingredient mirikizumab-mrkz, a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), a protein involved in inflammatory processes. It is indicated for treating adults with moderately to severely active ulcerative colitis. The treatment regimen typically begins with intravenous (IV) infusions during the induction phase, followed by subcutaneous injections for maintenance. The main types of omvoh formulations are tablets or capsules and injectables. Omvoh tablets or capsules offer convenient oral treatment for chronic inflammatory conditions, ensuring consistent dosing and ease of administration. It applies to various clinical indications, such as ulcerative colitis (UC), Crohn's disease, psoriasis, and others, and is used by several end users, including hospitals, clinics, pharmacies, and research institutions.

What Is The Omvoh Market Growth Forecast?

The growth in the forecast period can be attributed to growing adoption of targeted immunology therapies, expansion of biologic maintenance treatments, increasing focus on steroid-sparing regimens, rising investments in inflammatory disease drug development, continued innovation in monoclonal antibody platforms. Major trends in the forecast period include increasing adoption of il-23 targeted biologic therapies, rising focus on precision treatment for ibd, expansion of combination induction and maintenance regimens, growing use of injectable monoclonal antibodies, enhanced monitoring of treatment response.

Global Omvoh Market Segmentation

1) By Formulation: Tablets Or Capsules, Injectables 2) By Clinical Indication: Ulcerative Colitis (UC), Crohn's Disease, Psoriasis, Other Inflammatory Diseases 3) By End-User: Hospitals And Clinics, Pharmacies, Research Institutions

What Are The Drivers Of The Omvoh Market?

The rising autoimmune disease is expected to drive the growth of the omvoh market going forward. Autoimmune diseases are a group of conditions in which the immune system, which usually defends the body against infections and other harmful invaders, mistakenly attacks the body's healthy cells, tissues, or organs. The rise in autoimmune diseases can be attributed to several factors, including genetic predisposition, lifestyle factors, hormonal changes, and an aging population. Omvoh helps by restoring immune balance, neutralizing harmful antibodies, providing passive immunity, alleviating symptoms, reducing inflammation, and preventing further tissue damage in autoimmune diseases. For instance, in July 2024, according to the National Health Service (NHS) England, a UK-based government department, multiple sclerosis affects over 150,000 people in the UK, with more than 120,000 in England, and is more prevalent in women. Approximately 135 new diagnoses are made each week, highlighting its significant impact on the population. Therefore, the rise of autoimmune diseases will drive the growth of the omvoh industry. The rising healthcare expenditure will significantly drive the growth of the omvoh market in the future. Healthcare expenditure is the overall spending on medical care, treatments, and healthcare facilities within a specific economy or system. The rise in healthcare expenditure is driven by factors such as aging populations, increased prevalence of chronic diseases, advancements in medical technology, and higher patient expectations for quality care. Increased healthcare spending drives investment in autoimmune disease management, improving the accessibility of treatments like Omvoh, which regulate immune responses and enhance patient outcomes. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, the rising healthcare expenditure drives the growth of the omvoh industry.

Key Players In The Global Omvoh Market

Major companies operating in the omvoh market are Eli Lilly and Company

Global Omvoh Market Trends and Insights

Major companies operating in the Omvoh market are focusing on developing innovative solutions, such as advanced interleukin-23p19 (IL-23p19) antagonists, to meet the rising demand for targeted autoimmune therapies that provide deeper inflammation control and improved long-term patient outcomes. IL-23p19 antagonists block the p19 subunit of the IL-23 cytokine to reduce inflammatory signaling, offering a more selective and potentially better-tolerated approach compared with broader immunosuppressive treatments. For instance, in December 2024, Eli Lilly and Company, a US-based pharmaceutical company, announced that Omvoh has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for approval in the European Union for the treatment of adults with moderately to severely active Crohn's disease. This recommendation is supported by data from the Phase 3 VIVID-1 trial, which demonstrated significant improvements in clinical and endoscopic outcomes compared to placebo and an active control.

Regional Insights

North America was the largest region in the omvoh market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Omvoh Market?

The omvoh market consists of sales of subcutaneous injections, intravenous infusion bags, and lyophilized powder. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Omvoh Market Report 2026?

The omvoh market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the omvoh industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.